Plethora of Agents, Targets, and Side Effects in Metastatic Renal Cell Carcinoma

The plethora of novel agents recently approved for the management of metastatic renal cell carcinoma (RCC) has transformed the therapeutic landscape in this disease. These agents target various pathways, resulting in a wide range of side effects. While direct VEGF inhibition with anti-VEGF monoclonal antibodies is primarily associated with specific side effects, non-VEGF-related side effects are observed with agents inhibiting multiple receptor tyrosine kinases and mammalian target of rapamycin inhibitors. Understanding the mechanisms of action (MoA) of these novel therapies may help predict side effects, develop tolerable combinations, and improve patient selection and side-effect management.

Key Takeaways:

• The surge in novel agents for metastatic RCC has led to a diverse range of side effects, including proteinuria, hypertension, minor bleeding events, diarrhea, skin rash, stomatitis, hand-foot skin reaction, hypothyroidism, and haematological and metabolic abnormalities.
• Direct VEGF inhibition with anti-VEGF monoclonal antibodies is primarily associated with specific side effects, such as proteinuria, hypertension, and minor bleeding events.
• Non-VEGF-related side effects are observed with agents inhibiting multiple receptor tyrosine kinases (sunitinib, sorafenib, axitinib, and pazopanib) and mammalian target of rapamycin inhibitors (temsirolimus and everolimus).
• M. Schmidinger and colleagues from the Medical University of Vienna, Cancer Center, conducted the study and published it in Cancer Treatment Reviews (2010;36(5):416-24).
• The researchers emphasized the importance of understanding the mechanisms of action (MoA) of these novel therapies to predict side effects, develop tolerable combinations, and improve patient selection and side-effect management.
• The hypothetical combinations of agents with acceptable tolerability and the goal of developing effective side-effect management strategies are crucial aspects of the study.

Statistics:

• 5 novel agents are mentioned in the study as being approved for metastatic RCC: bevacizumab, sunitinib, sorafenib, axitinib, and pazopanib.
• 4 side effects are specifically mentioned as being directly associated with VEGF inhibition: proteinuria, hypertension, minor bleeding events, and proteinuria.
• The non-VEGF-related side effects account for a wide range of adverse effects: diarrhoea, skin rash, stomatitis, hand-foot skin reaction, hypothyroidism, and haematological and metabolic abnormalities.

Sources:

• Schmidinger M, et al. (2010). Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews, 36(5), 416-424.